J Infect Dis: Recombinant bubble-ventitis virus - immune-to-immune, heterogeneous and safety analysis of the Zaire Ebola virus envelope glycoprotein vaccine.
-
Last Update: 2020-07-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
!---- This dual-blind study assessed the immunogenicity, batch consistency and safety of the recombinant bubbly oral itisvirus-Zaire Ebola virus-Zaire Endomeleta Vaccine (rVSV G-ZEBOV-GP)1197 healthy adults were randomly 2:2:2:2:1 receiving 3 consistency batches of rVSV G-ZEBOV-GP (2 x 107 plaque formation units (pfu), high dose 1 x 108 pfu or one placeboAntibody response sat before/after vaccination (28 days, 6 months; 12, 18 and 24 months) in a subset of sn s566The results showed that the ZEBOV-GP enzyme-linked immunosorption test (ELISA) geometric average titness (GMTs) increased by 28 days after vaccination in all rVSV-G-ZEBOV-GP groups and continued for 24 months3 production batches showed the same immunogenicity at 28 daysIn all rVSV-G-ZEBOV-GP groups, neutralizing antibody GMTs increased within 28 days, peaked within 18 months and did not decrease within 24 monthsAt 28 days, the serum response of 94% of the recipients (ZEBOV-GP ELISA, increased by 2 times, titer is 200 EU/mL), and at 24 months the reaction of the recipients was sustained by 91%A woman's history of gender and arthritis is a potentially dangerous factor for post-vaccination arthritisIn summary, the results show that the immune response to rVSV G-ZEBOV-GP lasts for 24 monthsImmunogenicity and safety results support the continued development of rVSV G-ZEBOV-GP
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
